The FDA approved the first at-home screening test for which type of cancer in 2025, developed by Teal Health?

In May 2025, the U.S. Food and Drug Administration (FDA) granted approval to Teal Health for its innovative at-home screening test for cervical cancer. This marks a significant advancement in women's health, offering a convenient and private alternative to traditional in-clinic screenings. The device, known as the Teal Wand, allows individuals to collect a vaginal sample at home, which is then sent to a certified laboratory for analysis. The test specifically screens for high-risk types of human papillomavirus (HPV), the primary cause of nearly all cervical cancers.

Cervical cancer is one of the most preventable cancers through regular screening, yet a significant number of women in the United States are behind on their recommended screenings. Barriers such as scheduling difficulties, lack of time off work, or discomfort with in-clinic examinations often contribute to these missed appointments. The Teal Wand addresses these challenges by providing an accessible and comfortable option, potentially increasing screening rates and leading to earlier detection of precancerous conditions.

The FDA's approval of the Teal Wand was supported by the SELF-CERV study, a large comparative trial that demonstrated the at-home collected samples have the same accuracy as those collected by a clinician. The device utilizes the same highly accurate HPV tests recommended by medical guidelines and used in doctor's offices, ensuring reliable results. While the Teal Wand requires a prescription and includes an end-to-end telehealth service for virtual consultations, result reviews, and follow-up care, it empowers women to take a more proactive role in their cervical cancer prevention from the privacy of their homes. This development is expected to make a substantial impact on public health by making vital screenings more accessible.